Health technology firm Royal Philips partnered with artificial intelligence (AI) technology company PathAI to develop diagnostic solutions for diseases such as cancer.
The firms will work towards applying the AI to massive pathology data sets by building deep learning applications in computational pathology for better diagnostic and treatment decisions.
Applications for automatic detection and quantification of cancerous lesions in breast cancer tissue will initially be developed.
Pharmaceutical firm Bristol-Myers Squibb (BMS) invested in life sciences company Grail to develop diagnostics for cancer detection.
Grail combines the high-intensity cancer DNA sequencing, computer science and large clinical studies to develop highly sensitive blood tests that detect cancer in its early stages.
Through the new diagnostic platform, the company aims to provide early intervention of the disease with targeted therapies.
A clinical trial (BEST 3) funded by Cancer Research UK initiated across GP surgeries in the country to evaluate the Cytosponge test developed by MRC Cancer Unit of the University of Cambridge.
The Cytosponge test is designed as a less invasive way to detect Barrett’s oesophagus, which is believed to enhance the risk of oesophageal cancer.
Aimed to identify changing oesophageal cells in patients with acid reflux symptoms, the trial will assess the ability of the test to increase the number of diagnoses in primary care.
Charity organisation Arthritis Research UK partnered with IBM to develop a virtual personal assistant powered by Watson Health, to provide information and advice for people with arthritis.
The new initiative aims to offer access to personalised information from the Arthritis Research UK website in a form that is similar to a natural conversation.
Accessible on mobile phones and computers, the service does not require download of an app.
The researchers at University of California, Los Angeles (UCLA) in the US developed a new technique to identify the presence of DNA biomarkers of a disease using cellphone technology.
The new method utilises the sensors and optics of cellphones to interpret light generated by a new detector dye mixture that is designed to report the presence of DNA molecules with a bright signal.
The standard diagnostic tests require amplification of the number of nucleic acids, as the samples consist of very small amounts of nucleic acids related to a disease.
Quansys Biosciences and non-profit health organisation PATH developed a new multiplex diagnostic tool Q-Plex Micronutrient Array to fight against malnutrition and improve the health of women and children.
The new tool is designed to simultaneously detect up to seven nutrition-related biomarkers, and malaria infection in a single sample of human serum.
The Q-Plex Micronutrient Array will enable researchers to compile national data on the status of micronutrient deficiency for implementing and assessing targeted interventions.
Monitoring technologies firm Masimo launched the RD SedLine EEG sensor in the US to complement Masimo SedLine brain function monitoring and Masimo O3 regional oximetry.
SedLine and O3 are designed for simultaneous monitoring of the brain function on the Masimo Root monitoring platform.
With a repositioned, colour-coded sensor cable connection, the RD SedLine EEG sensor can be laid on the patient’s head and its soft foam pads ensure decrease of discomfort upon application.
Canada-based diagnostics company SQI Diagnostics signed an agreement with an undisclosed US-based firm to enhance predictive diagnostics for cardiac events.
Under the agreement, SQI will convert the customer's multi-biomarker test into an SQI-based multiplex test, and the kits will be manufactured at SQI's Toronto facility.
The collaboration also requires SQI to automate the test on its sqidlite system, which would later be divested to the customer to perform the tests at its CLIA laboratory.
Molecular diagnostics firm Myriad Genetics introduced its EndoPredict test in the US for patients with ER+ HER2- early-stage breast cancer.
EndoPredict is a second-generation, multigene test designed to predict the ten-year risk of disease recurrence after surgery and determine the patients who can safely drop adjuvant chemotherapy.
The test provides information to establish personalised treatment plans for the patients.
Munich Leukemia Laboratory (MLL) entered a research collaboration with IBM Watson and Illumina to enhance diagnostics and develop personalised treatment tools for leukemia and lymphoma.
The new cognitive technology prototype will focus on aiding researchers in leukemia treatment.
Illumina will provide its NovaSeq technology to MLL, which plans to use the technology to sequence samples from its biobank of more than 500,000 cases.